Skip to main content

Wixela Inhub FDA Approval History

FDA Approved: Yes (First approved January 30, 2019)
Brand name: Wixela Inhub
Generic name: fluticasone propionate and salmeterol
Dosage form: Inhalation Powder
Company: Mylan N.V.
Treatment for: Asthma, COPD

Wixela Inhub (fluticasone propionate and salmeterol) is a corticosteroid and long-acting beta2-adrenergic agonist (LABA) combination indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Wixela Inhub is the first approved generic version of Advair Diskus.

Development timeline for Wixela Inhub

DateArticle
Jan 31, 2019Approval FDA Approves Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), First Generic of Advair Diskus

See also

Wixela Inhub (fluticasone propionate and salmeterol) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer